CIAM
ENTA icon

Caitong International Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Caitong International Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117 Buy
+8
New +$108 ﹤0.01% 2138
2025
Q3 		– Sell
-195
Closed -$1.47K – 2107
2025
Q2 		$1.47K Sell
195
-1,245
-86% -$7.49K ﹤0.01% 1472
2025
Q1 		$7.95K Buy
1,440
+1,288
+847% +$7.96K 0.01% 914
2024
Q4 		$874 Buy
+152
New +$1.46K ﹤0.01% 1357

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Caitong International Asset Management's ENTA Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Enanta Pharmaceuticals (ENTA) in Q2 2026: 8 shares worth $117. The stake represents ﹤0.01% of the portfolio and ranks #2138 among its holdings. This is a return to the name: Caitong International Asset Management previously reported a position in ENTA as recently as Q2 2025.

Caitong International Asset Management first reported a position in ENTA in Q4 2024 and has held it in 4 quarters since. The position peaked at $7.95K in Q1 2025. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Caitong International Asset Management held 8 shares of Enanta Pharmaceuticals worth $117 as of Q2 2026.
  • Enanta Pharmaceuticals was a new Caitong International Asset Management position in Q2 2026.
  • Enanta Pharmaceuticals made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2138 holding.
  • Caitong International Asset Management first reported a position in Enanta Pharmaceuticals in Q4 2024 and has held it in 4 quarters since.
  • Caitong International Asset Management's Enanta Pharmaceuticals position peaked at $7.95K in Q1 2025.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.